Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Covington
US Department of Justice
QuintilesIMS
McKesson
Harvard Business School

Generated: April 25, 2019

DrugPatentWatch Database Preview

Valeant Pharm Intl Company Profile

« Back to Dashboard

What is the competitive landscape for VALEANT PHARM INTL, and what generic and branded alternatives to VALEANT PHARM INTL drugs are available?

VALEANT PHARM INTL has forty-three approved drugs.



Summary for Valeant Pharm Intl
US Patents:0
Tradenames:36
Ingredients:31
NDAs:43

Drugs and US Patents for Valeant Pharm Intl

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharm Intl QUINIDINE SULFATE quinidine sulfate TABLET;ORAL 083393-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Pharm Intl ZELAPAR selegiline hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021479-001 Jun 14, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Pharm Intl VIRAZOLE ribavirin FOR SOLUTION;INHALATION 018859-001 Dec 31, 1985 AN RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Pharm Intl LIBRIUM chlordiazepoxide hydrochloride CAPSULE;ORAL 012249-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Valeant Pharm Intl DALMANE flurazepam hydrochloride CAPSULE;ORAL 016721-002 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for Valeant Pharm Intl

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharm Intl PERMAX pergolide mesylate TABLET;ORAL 019385-003 Dec 30, 1988 5,114,948 ➤ Try a Free Trial
Valeant Pharm Intl VIRAZOLE ribavirin FOR SOLUTION;INHALATION 018859-001 Dec 31, 1985 RE29835 ➤ Try a Free Trial
Valeant Pharm Intl VIRAZOLE ribavirin FOR SOLUTION;INHALATION 018859-001 Dec 31, 1985 4,211,771 ➤ Try a Free Trial
Valeant Pharm Intl DALMANE flurazepam hydrochloride CAPSULE;ORAL 016721-002 Approved Prior to Jan 1, 1982 4,316,897 ➤ Try a Free Trial
Valeant Pharm Intl PERMAX pergolide mesylate TABLET;ORAL 019385-001 Dec 30, 1988 5,114,948 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for VALEANT PHARM INTL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe For Inhalation Solution 6 gm/vial ➤ Subscribe 2014-05-22
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Harvard Business School
UBS
Argus Health
Covington
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.